Kyorin Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kyorin Pharmaceutical Co., Ltd.
Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Immersive technologies are becoming a reality in the OR. In Vivo explores the future of surgery, profiling innovators of augmented reality technologies and exploring the promise and challenges surrounding robotic surgery as companies try to take technologies to the next level.
Digital Health Roundup, May 2021: Immersive Technologies In Surgery Suite, ‘Smart’ Toilets And Pills; New SaMD Cybersecurity Standards
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from May.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- ActivX Biosciences, Inc., KYORIN Holdings, Inc., Kyorin Rimedio